Nonhodgkin Lymphomas | Dr. Tony Talebi lectures on NonHodgkin Lymphomas
Dr. Tony Talebi lectures on NonHodgkin Lymphomas.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Myelodysplastic Syndrome | Dr. Tony Talebi discusses Myelodysplastic syndrome
Dr. Tony Talebi lectures on myelodysplastic syndrome.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Acute Lymphoblastic Leukemia | Dr Tony Talebi lectures on ALL
Dr. Tony Talebi lectures on acute lymphoblastic leukemia.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Stem Cell Transplantation | Dr. Tony Talebi lectures on Hematopoietic Stem Cell transplantation
Dr. Tony Talebi lectures on Hematopoietic stem cell transplantation.This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Colon Cancer | Dr. Tony Talebi discusses the Treatment of Stage IV Metastatic Colon Cancer
Dr Tony Talebi discusses the treatment of stage IV metastatic colon cancer with Dr Rocha Lima. For further discussion please visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of stage 4 metastatic colon cancer
Colon cancer is a common and lethal disease. It is estimated that approximately 141,210 new cases of large bowel cancer will be diagnosed in the United States in 2011, including about 101,000 colon and 40,000 rectal cancers. Approximately 49,380 Americans are expected to die of large bowel cancer this year. Although colon cancer mortality has been progressively declining since 1990 at a rate of about 3 percent per year, it still remains the second most common cause of cancer death in the US.
Screening with fecal occult blood testing, colonoscopy, or radiology can lead to diagnosis at an earlier stage of disease and therefore reduce mortality.
Symptoms of colon cancer are typically due to growth of the tumor into the lumen of the colon or adjacent structures. As a result, symptomatic presentation is often a manifestation of relatively advanced colon cancer. The majority of patients presenting with symptomatic colon cancer have blood in the stool, abdominal pain, otherwise unexplained iron deficiency anemia and/or a change in bowel habits
Surgical resection is the primary treatment modality for colon cancer, and outcome is most closely related to the extent of disease at presentation.
Here, Dr. Tony Talebi discusses the treatment of stage 4 metastatic colon cancer with Dr. Caio Rocha Lima, professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including diagnosis, staging, genetic implications, biopsy, surgery, and chemotherapy including new biologic treatments bevacizumab (Avastin), cetuximab (Erbitux), panitumumab (Vectibix) in EGFR wild type colon cancer in addition to FOLFOX and FOLFIRI chemotherapy.
Dr. Caio Rocha Lima Credentials:
Board Certifications
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Title
Professor of Medicine
Co-leader of Phase I clinical trials
Acute Leukemia | Dr. Tony Talebi lectures on Acute Myelogenous Leukemia
Dr. Tony Talebi lectures on AML.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Myeloma | Dr. Tony Talebi discusses treatment of multiple myeloma patients with Dr Ratzan
Dr Tony Talebi discusses treatment of multiple myeloma in non stem cell transplantation candidate patients with Dr Ratzan. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of multiple myeloma
Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin antibody. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, and/or pathologic fractures.
The diagnosis of multiple myeloma is often suspected because of one (or more) of the following clinical presentations.
1-Bone pain with lytic lesions discovered on routine skeletal films.
2-An increased total serum protein concentration and/or the presence of a monoclonal protein in the urine or serum.
3-High Calcium levels (Hypercalcemia), which is either symptomatic or discovered incidentally.
4-Acute kidney failure or worsening kidney function.
It is also important to evaluate patients suspected of having MM in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course.
There have many been recent treatments that have made a substantial impact in the treatment of multiple myeloma in the last several years.
Here, Dr. Tony Talebi discusses the treatment of non stem cell transplantation candidate patient with multiple myeloma with Dr. Judy Ratzan, associate professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including diagnosis, staging, imaging for, and treatment of multiple myeloma.
Treatments for myeloma including melphalan, bortezomib (Velcade), lenalidomide (Revlimid), zometa, dexamethasone, thalidomide, radiation therapy and stem cell transplantation will be discussed.
Dr. Judy Ratzan credentials:
Board Certifications
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Pancreatic Cancer | Dr Tony Talebi discusses Treatment of Metastatic Pancreatic Cancer
Dr Tony Talebi discusses management of metastatic pancreatic cancer with Dr Montero. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of metastatic stage 4 pancreatic cancer
Cancer of the pancreas is the fourth leading cause of cancer-related death in the United States and is second only to colorectal cancer as a cause of digestive cancer-related death. The majority of these tumors are adenocarcinomas arising from the ductal lining of the pancreatic epithelial cells.
Surgical resection is the only potentially curative treatment. Unfortunately, because of the late presentation of the disease, only 15 to 20 percent of patients are candidates for pancreatectomy. The prognosis of pancreatic cancer is poor even in those with potentially resectable disease. The five-year survival following pancreaticoduodenectomy (Whipple procedure) is only about 25 to 30 percent for node-negative and 10 percent for node-positive tumors.
Encasement of the arteries and veins in the vicinity of the pancreas generally make the tumor not resectable although each case has to be reviewed by an experienced surgeon.
Here, Dr. Tony Talebi discusses the treatment of metastatic stage 4 pancreatic cancer with Dr. Alberto Montero, assistant professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including symptoms of, diagnosis, staging, whipple surgery, radiation therapy and chemotherapy for pancreatic cancer.
Dr. Alberto Montero Credentials:
Board Certifications
American Board of Internal Medicine
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Education
University of Texas MD Anderson Cancer Center
Houston, TX
Hematology/Oncology 2005
University of Texas MD Anderson Cancer Center
Houston, TX
Hematology/Oncology 2005
University of Texas Health Science Center
Houston, TX Internal Medicine Residency
2002
University of Texas Medical Branch
Galveston, TX M.D.
1999
University of Texas
Austin, TX B.A. Philosophy 1994
Hodgkin Lymphoma | Dr. Tony Talebi lectures on Hodgkin Lymphoma
Dr. Tony Talebi lectures on Hodgkin Lymphoma.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Anemias | Dr. Tony Talebi lectures on Underproduction Anemias
Dr. Tony Talebi lectures on underproduction anemias.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Kidney Cancer | Dr. Tony Talebi discusses the Treatment of Stage 4 Metastatic Renal Cell Carcinoma
Dr. Tony Talebi discusses the management of stage 4, metastatic kidney cancer with Dr. Merchan. For further information visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of metastatic stage 4 kidney cancer
Kidney cancer or Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary kidney (renal) neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare.
Patients with kidney cancer or RCC can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease.
Patients with localized disease can present with a wide array of symptoms and/or laboratory abnormalities, or they may be diagnosed incidentally. The most common presenting symptoms were blood in the urine (hematuria), abdominal mass, pain, and weight loss.
For patients with isolated, solid kidney masses, resection with either a partial or complete nephrectomy is preferred to biopsy because it provides both the diagnosis and definitive treatment.
Here, Dr. Tony Talebi discusses the treatment of metastatic stage 4 kidney cancer (RCC) with Dr. Jaime Merchan, an assistant professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including symptoms, diagnosis, staging, surgery, RFA, high dose IL-2, and chemotherapy treatment for kidney cancer or renal cell carcinoma.
Dr. Jaime Merchan credentials:
Certifications
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Specialties
Internal Medicine
Hematology/Oncology - Internal Medicine
Roles
Assistant Professor of Clinical Medicine
Clinical Interests
Gastrointestinal and Genitourinary Malignancies
Research Interests
Tumor Angiogenesis, vascular targeting, experimental therapeutics
Education
2003 Masters
Harvard Medical School and Massachusetts Institute of Technology
1998 Fellowship
Beth Israel Deaconess Med Ctr/Harvard Medical School
1997 Chief Resident
U of Miami/VA Medical Center
1995 Residency
U of Miami/Jackson Memorial Med Center
1994 Internship
U of Miami/Jackson Memorial Med Ctr
1992 M.D.
Universidad Catolica de Santiago de Guayaquil
Plasma Cell Disorders | Dr. Tony Talebi lectures on Plasma Cell Disorders
Dr. Tony Talebi lectures on Plasma Cell Disorders such as Multiple Myeloma.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Hodgkin Lymphoma | Dr. Tony Talebi discusses What is Hodgkin Lymphoma?
Dr. Tony Talebi discusses What is Hodgkin Lymphoma? with Dr. Ann Morhbacher. For further information visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Hodgkin lymphoma
Hodgkin lymphoma accounts for approximately 10 percent of all lymphomas and approximately 0.6 percent of all cancers diagnosed in the developed world annually. This amounts to approximately 8830 new cases and about 1300 deaths due to HL in the United States annually.
The majority of patients with classical Hodgkin lymphoma present with painless localized enlarged lymph nodes, typically involving the cervical (neck) region.
Hodgkin lymphoma arises from germinal center or post-germinal center B cells in the lymph nodes. Hodgkin lymphoma has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells.
The diagnosis of Hodgkin lymphoma is made by the evaluation of involved tissue, usually a lymph node biopsy. Excisional biopsies are preferred and large core needle biopsies may be adequate in select cases.
Here, Dr. Tony Talebi discusses the general concepts of Hodgkin lymphoma with Dr. Ann Morhbacher, associate professor of medicine at the University of Southern California and a top US doctor as per US world news and world report magazine. The discussion includes symptoms, diagnosis, staging, genetic implications, secondary cancers and treatment of hodgkin lymphoma.
Dr. Ann Morhbacher credentials:
Title:
Associate Professor of Clinical Medicine
Locations:
University of Southern California (USC) Norris Comprehensive Cancer Center
Specialties:
Hematology and Oncology
Background:
Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin's lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.
Education:
Harvard and Radcliffe Colleges, Boston, MA, B.A., 1983
Doctor of Medicine, Harvard Medical School, Boston, MA, 1987
Internships:
Brigham and Women's Hospital, Boston, MA, 1983 - 1984
Residencies:
Brigham and Women's Hospital (Internal Medicine), Boston, MA, 1987 - 1990
Fellowships:
Clinical Medicine Fellow, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1990 - 1993
Clinical Oncology and Tumor Immunology Fellow, Dana-Farber Cancer Institute, Boston, MA, 1990 - 1993
Board Certification:
Medical Oncology
Internal Medicine
Professional Society Memberships:
Massachusetts Medical Society, 1985
American Society of Hematology, 1994
Southwest Oncology Group, 1994
Awards:
A.B. Magna Cum Laude, 1983
Harvard College Scholarship, 1983
ASCO career Development Award, 1995
Dr. Mohrbacher was voted a Top Doctor by Pasadena Magazine in 2011.
Kidney Cancer | Dr. Tony Talebi discusses What is Kidney Cancer? with Dr. Jaime Merchan.
Dr Tony Talebi discusses What is Kidney Cancer? with Dr. Jaime Merchan. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
What is Kidney Cancer?
Kidney cancer or Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary kidney (renal) neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare.
Kidney Cancer Symptoms
Patients with kidney cancer or RCC can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease.
Patients with localized disease can present with a wide array of symptoms and/or laboratory abnormalities, or they may be diagnosed incidentally. The most common presenting symptoms were blood in the urine (hematuria), abdominal mass, pain, and weight loss.
Kidney Cancer Treatments
For patients with isolated, solid kidney masses, resection with either a partial or complete nephrectomy is preferred to biopsy because it provides both the diagnosis and definitive treatment.
Here, Dr. Tony Talebi discusses general concepts of kidney cancer (RCC) with Dr. Jaime Merchan, an assistant professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including symptoms, diagnosis, staging, surgery, RFA, high dose IL-2, and chemotherapy treatment for kidney cancer or renal cell carcinoma.
Dr. Jaime Merchan credentials:
Certifications
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Specialties
Internal Medicine
Hematology/Oncology - Internal Medicine
Roles
Assistant Professor of Clinical Medicine
Clinical Interests
Gastrointestinal and Genitourinary Malignancies
Research Interests
Tumor Angiogenesis, vascular targeting, experimental therapeutics
Education
2003 Masters
Harvard Medical School and Massachusetts Institute of Technology
1998 Fellowship
Beth Israel Deaconess Med Ctr/Harvard Medical School
1997 Chief Resident
U of Miami/VA Medical Center
1995 Residency
U of Miami/Jackson Memorial Med Center
1994 Internship
U of Miami/Jackson Memorial Med Ctr
1992 M.D.
Universidad Catolica de Santiago de Guayaquil
Testicular Cancer | Dr. Tony Talebi discusses the Treatment of Seminomatous Testicular Cancer
Dr Tony Talebi discusses the Treatment of Seminomatous Testicular Cancer with Dr Benedetto. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of seminoma testicular cancer
Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for about 1 percent of all cancers in men. Germ cell tumors (GCTs) account for 95 percent of testicular cancers. They may consist of one predominant histologic pattern, or represent a mix of multiple histologic types.
For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present), and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is about one.
Testicular cancer has become one of the most curable of solid neoplasms because of remarkable treatment advances beginning in the late 1970s.
Here, Dr. Tony Talebi discusses the treatment of seminoma testicular cancer with Dr. Pasquele Benedetto, professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center, including symptoms, diagnosis, staging, prognosis, surgery, radiation therapy and chemotherapy for seminoma testicular cancer.
Dr. Pasquele Benedetto credentials:
Board Certifications:
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Education:
Georgetown University
Washington, DC Undergraduate
Weill Medical College of Cornell University
New York, NY Graduate
Johns Hopkins Hospital
Baltimore, MD Residency
Memorial Sloan-Kettering Cancer Center
New York, NY Fellowship
Hodgkin Lymphoma | Dr. Tony Talebi discusses the Treatment of Stage 1-2 Hodgkin Lymphoma
Dr. Tony Talebi discusses the Treatment of Stage 1-2 Hodgkin Lymphoma with Dr Morhbacher. For further information visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Hodgkin lymphoma
Hodgkin lymphoma accounts for approximately 10 percent of all lymphomas and approximately 0.6 percent of all cancers diagnosed in the developed world annually. This amounts to approximately 8830 new cases and about 1300 deaths due to HL in the United States annually.
The majority of patients with classical Hodgkin lymphoma present with painless localized enlarged lymph nodes, typically involving the cervical (neck) region.
Hodgkin lymphoma arises from germinal center or post-germinal center B cells in the lymph nodes. Hodgkin lymphoma has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells.
The diagnosis of Hodgkin lymphoma is made by the evaluation of involved tissue, usually a lymph node biopsy. Excisional biopsies are preferred and large core needle biopsies may be adequate in select cases.
Here, Dr. Tony Talebi discusses the general concepts of Hodgkin lymphoma with Dr. Ann Morhbacher, associate professor of medicine at the University of Southern California and a top US doctor as per US world news and world report magazine. The discussion includes symptoms, diagnosis, staging, genetic implications, secondary cancers and treatment of hodgkin lymphoma.
Dr. Ann Morhbacher credentials:
Title:
Associate Professor of Clinical Medicine
Locations:
University of Southern California (USC) Norris Comprehensive Cancer Center
Specialties:
Hematology and Oncology
Background:
Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin's lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.
Education:
Harvard and Radcliffe Colleges, Boston, MA, B.A., 1983
Doctor of Medicine, Harvard Medical School, Boston, MA, 1987
Internships:
Brigham and Women's Hospital, Boston, MA, 1983 - 1984
Residencies:
Brigham and Women's Hospital (Internal Medicine), Boston, MA, 1987 - 1990
Fellowships:
Clinical Medicine Fellow, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1990 - 1993
Clinical Oncology and Tumor Immunology Fellow, Dana-Farber Cancer Institute, Boston, MA, 1990 - 1993
Board Certification:
Medical Oncology
Internal Medicine
Professional Society Memberships:
Massachusetts Medical Society, 1985
American Society of Hematology, 1994
Southwest Oncology Group, 1994
Awards:
A.B. Magna Cum Laude, 1983
Harvard College Scholarship, 1983
ASCO career Development Award, 1995
Dr. Mohrbacher was voted a Top Doctor by Pasadena Magazine in 2011.
Myeloma | Dr. Tony Talebi discusses What is Multiple Myeloma? with Dr Judy Ratzan
Dr Tony Talebi discusses what is Multiple Myeloma with Dr Judy Ratzan. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
What is multiple myeloma?
Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin antibody. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, and/or pathologic fractures.
The diagnosis of multiple myeloma is often suspected because of one (or more) of the following clinical presentations.
1-Bone pain with lytic lesions discovered on routine skeletal films.
2-An increased total serum protein concentration and/or the presence of a monoclonal protein in the urine or serum.
3-High Calcium levels (Hypercalcemia), which is either symptomatic or discovered incidentally.
4-Acute kidney failure or worsening kidney function.
It is also important to evaluate patients suspected of having MM in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course.
There have many been recent treatments that have made a substantial impact in the treatment of multiple myeloma in the last several years.
Here, Dr. Tony Talebi discusses general concepts of multiple myeloma with Dr. Judy Ratzan, associate professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including diagnosis, staging, imaging for, and treatment of multiple myeloma.
Dr. Judy Ratzan credentials:
Board Certifications
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Consultative Hematology | Dr. Tony Talebi lectures on Consultative Hematology
Dr. Tony Talebi lectures on consultative Hematology.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Marrow Failure Syndromes | Dr. Tony Talebi lectures on Bone Marrow Failure Syndromes
Dr. Tony Talebi lectures on Bone Marrow Failure Syndromes.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Integrative medicine | Dr Tony Talebi discusses What is Integrative Medicine? with Dr. Eugene Ahn.
Dr Tony Talebi discusses Integrative Medicine with Dr. Eugene Ahn. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
What is Integrative Medicine:
Complementary and alternative medicine is defined by the National Center for Complementary and Alternative Medicine as a group of diverse medical and health care systems, practices, and products that are not normally considered to be conventional medicine. Included in this type of therapy are herbs, acupuncture, chiropractic, and massage, among others. Use of these therapies is common in the general population.
The use of integrative medicine is widespread and increasing. Multiple studies have found that within one year, up to 90 percent of patients with cancer used an integrative medicine approach for at least a part of their therapy. However, patients may not reveal the use of complementary medicine unless specifically asked. In one study, disclosure of the use of these therapies increased from 7 to 43 percent when directed questions were added to standard history taking. Unfortunately, communication between oncologists and patients about complementary is poor, infrequent, and mostly initiated by patients or their kin.
Users of integrative and complementary medicine are generally not dissatisfied with conventional medicine but find alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life. Factors reported to be associated with use of CAM therapies in cancer patients include:
Increased psychosocial stress (eg, anxiety, depression)
Being given a less hopeful prognosis
Having the feeling of nothing to lose
Attending support groups
Age (younger versus older) and gender (women more than men)
Despite the current popularity of CAM, most mainstream oncologists have little understanding of these therapies. However, patients with cancer report feeling that their doctors should be more interested in, more informed about, and more willing to discuss unconventional therapies.
Commonly used complementary medicines and treatments include Essiac, Mistletoe, PC-SPES, Sho-saiko-to, St. John's wort, Astragalus, Melatonin, Shark and bovine cartilage, Hydrazine, Coenzyme Q10, Thymus extracts, Shiitake mushroom extract, Acupuncture, Hypnotherapy, Behavioral intervention, Relaxation therapy, Aromatherapy , Self-help and support groups, Ginseng and fatigue, Fish oil for symptom control , vitamins, and immunostimulating herb.
Here, Dr. Tony Talebi discusses the general concepts of what is integrative medicine with Dr. Eugene Ahn, assistant professor of medicine at the University of Miami Comprehensive Cancer Center and a specialist in integrative medicine.
Dr. Ahn credentials:
Certifications American Board of Internal Med-Infectious
DiseasesAmerican Board of Internal Med-Medical Oncology
Specialties
Hematology/Oncology - Internal Medicine
Roles
Assistant Professor
Clinical Interests
Breast cancer, Infectious Diseases
Research Interests
Impact of cognitive and spiritual therapy as adjuncts to standard of care for metastatic, incurable cancer on long-term outcomes including survival and quality of life.
Education
2007 Fellowship
University of Miami
2000 Fellowship
University of Miami
1999 Residency
University of Utah
1998 Internship
University of Utah
1997 M.D.
University of Miami School of Medicine
Undergraduate
Yale University
Testicular Cancer | Dr. Tony Talebi discusses the treatment of Non Seminoma Testicular Cancer
Dr Tony Talebi discusses the treatment of Non Seminoma Testicular Cancer with Dr Benedetto. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of non seminoma testicular cancer
Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for about 1 percent of all cancers in men. Germ cell tumors (GCTs) account for 95 percent of testicular cancers. They may consist of one predominant histologic pattern, or represent a mix of multiple histologic types.
For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present), and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is about one.
Testicular cancer has become one of the most curable of solid neoplasms because of remarkable treatment advances beginning in the late 1970s.
Here, Dr. Tony Talebi discusses the treatment of non seminoma testicular cancer with Dr. Pasquele Benedetto, professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center, including symptoms, diagnosis, staging, prognosis, surgery, radiation therapy and chemotherapy for non seminoma testicular cancer.
Dr. Pasquele Benedetto credentials:
Board Certifications:
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Education:
Georgetown University
Washington, DC Undergraduate
Weill Medical College of Cornell University
New York, NY Graduate
Johns Hopkins Hospital
Baltimore, MD Residency
Memorial Sloan-Kettering Cancer Center
New York, NY Fellowship
Palliative Care | Dr Tony Talebi discusses What is Palliative Care? with Dr Stephen Bekanich
- Palliative Care. Dr Tony Talebi discusses What is Palliative Care? with Dr Stephen Bekanik. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
What is Palliative Care?
Definition
Palliative care (pronounced pal-lee-uh-tiv) is specialized medical care for people with serious illnesses. It is focused on providing patients with relief from the symptoms, pain, and stress of a serious illness—whatever the diagnosis. The goal is to improve quality of life for both the patient and the family.
Palliative care is provided by a team of doctors, nurses, and other specialists who work together with a patient's other doctors to provide an extra layer of support. It is appropriate at any age and at any stage in a serious illness and can be provided along with curative treatment.
Relieves suffering. Improves quality of life.
Palliative care treats people suffering from serious and chronic illnesses including cancer, cardiac disease such as Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), kidney failure, Alzheimer's, HIV/AIDS and Amyotrophic Lateral Sclerosis (ALS). Palliative care relieves the symptoms of these diseases, such as pain, shortness of breath, fatigue, constipation, nausea, loss of appetite and difficulty sleeping. It helps you gain the strength to carry on with daily life. It improves your ability to tolerate medical treatments. And it helps you have more control over your care by better understanding your choices for treatment options.
The point of palliative care is to relieve suffering and provide the best possible quality of life for both the patient and their family.
A Partnership of Patient, Specialists and Family
Palliative care is a partnership of patient, medical specialists and family. Usually a team of experts, including palliative care doctors, nurses and social workers, provides this care and works together with your own doctor. Chaplains, massage therapists, pharmacists, nutritionists and others may also be part of the palliative care team.
The palliative care team of specialists provides spends as much time as necessary with you and your family. The team supports you and your family every step of the way, not only by controlling your symptoms, but also by helping you to understand your treatment options and goals. Working with your doctor to provide an extra layer of support, the palliative care team provides:
Time for close communication
Expert management of pain and other symptoms
Help navigating the healthcare system
Guidance with difficult and complex treatment choices
Emotional and spiritual support for you and your family
Thanks to getpalliativecare.org for this information.
Hodgkin Lymphoma | Dr. Tony Talebi Discusses the Treatment of Stage 3-4 Hodgkin Lymphoma
Dr. Tony Talebi Discusses the Treatment of Stage 3-4 Hodgkin Lymphoma with Dr. Morhbacher. For further information visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of stage 3 and 4 Hodgkin lymphoma
Hodgkin lymphoma accounts for approximately 10 percent of all lymphomas and approximately 0.6 percent of all cancers diagnosed in the developed world annually. This amounts to approximately 8830 new cases due to Hodgkin in the United States annually.
The majority of patients with classical Hodgkin lymphoma present with painless localized enlarged lymph nodes, typically involving the cervical (neck) region.
Hodgkin lymphoma arises from germinal center or post-germinal center B cells in the lymph nodes. Hodgkin lymphoma has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells.
The diagnosis of Hodgkin lymphoma is made by the evaluation of involved tissue, usually a lymph node biopsy. Excisional biopsies are preferred and large core needle biopsies may be adequate in select cases.
Here, Dr. Tony Talebi discusses the treament of stage 3 and 4 Hodgkin lymphoma with Dr. Ann Morhbacher, associate professor of medicine at the University of Southern California and a top US doctor as per US world news and world report magazine. The discussion includes symptoms, diagnosis, staging, genetic implications, secondary cancers and treatment of hodgkin lymphoma.
Dr. Ann Morhbacher credentials:
Title:
Associate Professor of Clinical Medicine
Locations:
University of Southern California (USC) Norris Comprehensive Cancer Center
Specialties:
Hematology and Oncology
Background:
Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin's lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.
Education:
Harvard and Radcliffe Colleges, Boston, MA, B.A., 1983
Doctor of Medicine, Harvard Medical School, Boston, MA, 1987
Internships:
Brigham and Women's Hospital, Boston, MA, 1983 - 1984
Residencies:
Brigham and Women's Hospital (Internal Medicine), Boston, MA, 1987 - 1990
Fellowships:
Clinical Medicine Fellow, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1990 - 1993
Clinical Oncology and Tumor Immunology Fellow, Dana-Farber Cancer Institute, Boston, MA, 1990 - 1993
Board Certification:
Medical Oncology
Internal Medicine
Professional Society Memberships:
Massachusetts Medical Society, 1985
American Society of Hematology, 1994
Southwest Oncology Group, 1994
Awards:
A.B. Magna Cum Laude, 1983
Harvard College Scholarship, 1983
ASCO career Development Award, 1995
Dr. Mohrbacher was voted a Top Doctor by Pasadena Magazine in 2011.
Myeloma | Dr. Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan
Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Treatment of stem cell transplantation candidate patient with multiple myeloma
Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin antibody. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, and/or pathologic fractures.
The diagnosis of multiple myeloma is often suspected because of one (or more) of the following clinical presentations.
1-Bone pain with lytic lesions discovered on routine skeletal films.
2-An increased total serum protein concentration and/or the presence of a monoclonal protein in the urine or serum.
3-High Calcium levels (Hypercalcemia), which is either symptomatic or discovered incidentally.
4-Acute kidney failure or worsening kidney function.
It is also important to evaluate patients suspected of having MM in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course.
There have many been recent treatments that have made a substantial impact in the treatment of multiple myeloma in the last several years.
Here, Dr. Tony Talebi discusses the treatment of stem cell transplantation candidate patient with multiple myeloma with Dr. Judy Ratzan, associate professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including diagnosis, staging, imaging for, and treatment of multiple myeloma.
Treatments for myeloma including melphalan, bortezomib (Velcade), lenalidomide (Revlimid), zometa, dexamethasone, thalidomide, radiation therapy and stem cell transplantation will be discussed.
Dr. Judy Ratzan credentials:
Board Certifications
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Hemolytic Anemia | Dr Tony Talebi lectures on Hemolytic Anemia
Dr. Tony Talebi lectures on hemolytic anemia.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Laboratory Hematology | Dr. Tony Talebi lectures on Laboratory Hematology
Dr. Tony Talebi lectures on Laboratory Hematology.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Pancreatic Cancer | Dr Tony Talebi discusses the Treatment of Locally Advanced Pancreatic Cancer
Dr Tony Talebi discusses the management of locally advanced pancreatic cancer with Dr Montero. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084
Pancreatic cancer - Treatment of locally advanced stage 1 to 3
Cancer of the pancreas is the fourth leading cause of cancer-related death in the United States and is second only to colorectal cancer as a cause of digestive cancer-related death. The majority of these tumors are adenocarcinomas arising from the ductal lining of the pancreatic epithelial cells.
Surgical resection is the only potentially curative treatment. Unfortunately, because of the late presentation of the disease, only 15 to 20 percent of patients are candidates for pancreatectomy. The prognosis of pancreatic cancer is poor even in those with potentially resectable disease. The five-year survival following pancreaticoduodenectomy (Whipple procedure) is only about 25 to 30 percent for node-negative and 10 percent for node-positive tumors.
Encasement of the arteries and veins in the vicinity of the pancreas generally make the tumor not resectable although each case has to be reviewed by an experienced surgeon.
Here, Dr. Tony Talebi discusses the treatment of locally advanced stage 1 to 3, potentially curative, pancreatic cancer with Dr. Alberto Montero, assistant professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center including symptoms of, diagnosis, staging, whipple surgery, radiation therapy and chemotherapy for pancreatic cancer.
Dr. Alberto Montero Credentials:
Board Certifications
American Board of Internal Medicine
American Board of Internal Med-Medical Oncology
Practice Locations
University of Miami Sylvester Comprehensive Cancer Center
Education
University of Texas MD Anderson Cancer Center
Houston, TX
Hematology/Oncology 2005
University of Texas MD Anderson Cancer Center
Houston, TX
Hematology/Oncology 2005
University of Texas Health Science Center
Houston, TX Internal Medicine Residency
2002
University of Texas Medical Branch
Galveston, TX M.D.
1999
University of Texas
Austin, TX B.A. Philosophy 1994
Porphyrias | Dr. Tony Talebi lectures on Porphyrias
Dr. Tony Talebi lectures on porphyrias.
This lectures corresponds to the best selling book Hematology and Transfusion Medicine Board Review Made Simple.
For further lectures visit HemOnc101.com
Dr. Tony Talebi is a board certified Hematologist/Oncologist and owner of Miami Hematology and Oncology Associates, a Cancer Institute based in Homestead at 151 NW 11th street, Homestead Fl 33030.
His office number is 786-504-3084.
Prostate Cancer | Dr. Tony Talebi discusses Treatment of Stage 4 Hormone Resistant Prostate Cancer
Dr. Tony Talebi discusses management of stage 4 castrate resistant prostate cancer with Dr Singal. For further discussion visit
Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084